Decode Your Wellbeing

On June 9, 2026, doctors in a clinical trial run by Life Biosciences, the Boston company co-founded by the Harvard geneticist David Sinclair, gave the first patient a treatment called ER-100. It goes into the eye inside an engineered virus, stripped of its ability to cause infection, that carries three genes able to push an adult cell back toward a younger state. A course of the antibiotic doxycycline switches those genes on for eight weeks. The trial will enroll up to 18 people with glaucoma or a sudden optic-nerve stroke called NAION, at sites including Mass Eye and Ear in Boston and Columbia University in New York. Money moved fast. A week before that first dose, the startup NewLimit, co-founded by Coinbase chief executive Brian Armstrong, raised $435 million in a round led by Founders Fund that valued it at about $3.1 billion, and in May, Retro Biosciences, seeded with $180 million from OpenAI chief executive Sam Altman, said its new funding valued it at $1.8 billion.
On the surface, that sounds like age reversal arriving in people. The idea being tested, called partial reprogramming, holds that some of the wear of aging lives in the chemical tags that tell a cell which genes to use, and that those tags can be reset without erasing what the cell is. It has worked in mice and in dishes of human cells. In people, so far, it is a first safety test in a small number of eyes, and the danger researchers are watching for is a rejuvenated cell that forgets its job and turns cancerous. Evidence with decades behind it points somewhere plainer. In a Cleveland Clinic study of 122,007 people who ran on a treadmill until they had to stop, published in JAMA Network Open in 2018 by Kyle Mandsager and colleagues, the least fit died at more than four times the rate of the fittest in the years that followed.
Decode Your Wellbeing ran in eight parts during the week of July 20, 2026. Part 1 covers the reprogramming trial and the money behind it, and it separates new findings from old ones dressed up as news. Part 2 lays out the habits with the deepest human evidence for healthspan, meaning the years lived in good health: cardiorespiratory fitness, strength training, hearing, sleep, protein, and friendship and purpose. What does a biological age test actually measure? Part 3 answers that, from Steve Horvath’s first epigenetic clock at UCLA in 2013 to DunedinPACE, a tool built on a group of New Zealanders followed since their births in 1972, and it explains why one blood sample can read years apart on different clocks. Mitochondria, the parts of each cell that make its energy, are the subject of Part 4, which sets what exercise does for them beside what supplement trials have found.
Senescent cells come next. They are nicknamed zombie cells because they stop dividing but linger and leak inflammation, and Part 5 follows the research on them from mice in Jan van Deursen’s lab at the Mayo Clinic into human trials. Part 6 covers protein needs after 40 and the slow rise in inflammation with age that the Italian immunologist Claudio Franceschi named inflammaging in 2000. It also explains why recovery, with sleep at its center, is where training pays off. In Part 7, readers get a way to rank any longevity claim by how strong its human evidence is. Part 8 pulls the week together around what the series calls a barbell, with effort on the proven habits at one end and patient attention on the frontier science at the other. In that plan, the unproven products in the middle get as little money as possible.
Every part is journalism about published research, not medical advice, and any change to diet, exercise or supplements belongs in a conversation with a clinician who knows your history. Anyone holding a biological age result, or thinking about paying for one, may want to read Part 3 first. A companion series, The Longevity Marketplace, goes deeper into the clinics and products selling this science.